Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...
Sanofi: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most ...
Sanofi: Promising Growth with Strategic Developments and Robust Pipeline
Analyst Graham Parry from Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report) and keeping the price target ...
Daily5d
Sanofi gets USFDA Breakthrough Therapy designation for multiple sclerosis therapy Tolebrutinib
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Multiple Sclerosis News Today5d
Tolebrutinib for SPMS granted FDA breakthrough therapy designation
Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...
PMLiVE5d
Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS
Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib has been granted breakthrough therapy ...
Managed Healthcare Executive5d
Vaccination Not a Risk Factor for Pediatric-Onset MS, Study Finds
Previous studies have found no association between vaccination and MS in adults. To evaluate the association between ...